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To the Editor ,
Linear IgA bullous dermatosis (LAD) is an
acquired immunobullous dermatosis that relies
on direct immunofluorescence (DIF) testing
showing linear deposition of immunoglobulin
IgA along the basement membrane of the epi-
dermis for diagnosis1. We present a case that
highlights the utility of repeating the DIF testing
when initial immunofluorescence findings do
not support the clinical findings of drug-induced
LAD or contradict the histopathologic findings
in routinely stained sections.
A 74-year-old African-American female with
renal insufficiency and a stage four sacral
Fig. 1. Photographs taken at the time of presentation to consulting dermatologist. Note the grouping of tense blisters. Images taken
at patient’s (A) left axillary fold region and (B) left shoulder.
decubitus ulcer was hospitalized for new-onset
periodic fevers following a surgical repair with
flap closure. Her admitting team instituted
broad-spectrum antibiotics, to include van-
comycin, ciprofloxacin, piperacillin-tazobactam
and meropenem. The primary team observed
a rash four days into the start of the antibiotic
regimen and consulted dermatology for further
guidance.
Examination by a dermatologist revealed
broad, erythematous, edematous discrete and
coalescing plaques involving the neck, trunk
and proximal anterior shoulders (Fig. 1).
Areas of discrete vesicles were noted to involve
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flexural regions of the patient’s neck and
axilla. Mucosal surfaces, as well as the patient’s
face, back and distal extremities were spared.
Widespread epidermal loss and skin tenderness
were absent.
The consulting dermatologist favored a drug
eruption with early Stevens Johnson syndrome
(SJS) and LAD included in the differential diag-
nosis. While SJS was considered, the patient
lacked skin tenderness as well as mucosal involve-
ment, and the rapid time course to onset after
starting the antibiotics was not consistent with
SJS. LAD was favored because the patient was
on vancomycin, the most common offending
medication for drug-induced LAD. However, an
adverse reaction to other concomitant drugs was
considered. Cessation of antibiotics was advised
pending biopsy results. Two perilesional punch
biopsies showed a sub-epidermal split charac-
terized by a neutrophilic infiltrate and pustule
formation. The histopathologic differential diag-
nosis included bullous urticaria, bullous lupus,
Sweets syndrome or LAD. Surprisingly, initial
DIF staining was negative, with no reactants to
IgA, IgG, IgM or C3 observed.
LAD remained on the clinical differential in
light of the patient’s clinical and histopatho-
logic findings. The negative DIF result, however,
did not support this diagnosis, and, owing
to the patient’s interval clinical progres-
sion, she was transferred to a burn unit as
a precaution in the event that her eruption
progressed.
The patient’s skin exam subsequently stabi-
lized, with no further progression of vesicle
formation and all mucosal surfaces remained
spared. As the rash had not worsened, the
patient was transferred back to the medicine
ward. A repeat biopsy for DIF was obtained
from peri-lesional skin in an involved area
on the left anterior shoulder. The second
DIF, processed at the same lab as the first
biopsy, revealed prominent linear IgA depo-
sition along the dermal–epidermal junction,
establishing the diagnosis of drug-induced
LAD (Fig. 2).
It is noted that the patient’s history of renal dis-
ease may have contributed to the initial negative
DIF result due to an altered immune response
leading to consumption of complement proteins
and immunoglobulins. Alternatively, the initial
biopsy site may have missed the active inflam-
mation along the dermal–epidermal junction
observed in LAD.
In drug-induced LAD, cessation of the med-
ication responsible is often sufficient to stop
Fig. 2. A) Hematoxylin and eosin staining of biopsy tissue.
Note the sub-epidermal split indicated by asterisks. B) Positive
direct immunofluorescence (DIF) staining observed along
dermal-epidermal junction; IgA deposition was observed along
the roof of the blister.
progression2. In our patient, supportive care
with a topical steroid (triamcinolone 0.1%
ointment) was started as the vancomycin, the
most probable drug culprit, was discontinued.
The patient’s symptoms improved and the bul-
lae resolved completely with only superficial
post-inflammatory hyperpigmentation.
Little is reported in the literature regarding
false negative DIF testing based on biopsy site.
Our case highlights the utility of a second biopsy
when an initial DIF is negative. In addition, it
underscores that a false negative DIF result can
occur depending on the biopsy location, con-
founding immune dysregulation, or tissue qual-
ity and a second biopsy should be considered if
initial findings are negative.
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Disclaimer
The views expressed in this article are those of
the author and do not necessarily reflect the
official policy or position of the Department of
Defense, or the US Government. The authors
aremilitary service members or employees of the
US Government. Title 17, USC, § 105 provides
that ‘Copyright protection under this title is
not available for any work of the United States
Government.’ Title 17, USC, § 101 defines a
US Government work as a work prepared by
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